JP2020532545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532545A5 JP2020532545A5 JP2020512586A JP2020512586A JP2020532545A5 JP 2020532545 A5 JP2020532545 A5 JP 2020532545A5 JP 2020512586 A JP2020512586 A JP 2020512586A JP 2020512586 A JP2020512586 A JP 2020512586A JP 2020532545 A5 JP2020532545 A5 JP 2020532545A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- acceptable salt
- compound according
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 C*(C)*C(C)(C)*N(*)C(*)(CC1)CC(C)(*)CN1C(OC(C(F)(F)F)C(F)(F)F)=O Chemical compound C*(C)*C(C)(C)*N(*)C(*)(CC1)CC(C)(*)CN1C(OC(C(F)(F)F)C(F)(F)F)=O 0.000 description 9
- BOTQSJOGJLBLQM-UHFFFAOYSA-N Cc([s]c1ccc2)cc1c2Cl Chemical compound Cc([s]c1ccc2)cc1c2Cl BOTQSJOGJLBLQM-UHFFFAOYSA-N 0.000 description 1
- XTHDNFIOIFQTRA-UHFFFAOYSA-N Cc([s]c1ccccc11)c1[Cl]=C Chemical compound Cc([s]c1ccccc11)c1[Cl]=C XTHDNFIOIFQTRA-UHFFFAOYSA-N 0.000 description 1
- BLZKSRBAQDZAIX-UHFFFAOYSA-N Cc1cc2ccccc2[s]1 Chemical compound Cc1cc2ccccc2[s]1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 1
- DVUFTKULUBKXMS-UHFFFAOYSA-N Cc1cnc(cc2)[n]1cc2Cl Chemical compound Cc1cnc(cc2)[n]1cc2Cl DVUFTKULUBKXMS-UHFFFAOYSA-N 0.000 description 1
- DLTHEPWEENQLKV-UHFFFAOYSA-N Cc1cnc2[n]1cccc2 Chemical compound Cc1cnc2[n]1cccc2 DLTHEPWEENQLKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551721P | 2017-08-29 | 2017-08-29 | |
| US62/551,721 | 2017-08-29 | ||
| PCT/US2018/048372 WO2019046318A1 (en) | 2017-08-29 | 2018-08-28 | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532545A JP2020532545A (ja) | 2020-11-12 |
| JP2020532545A5 true JP2020532545A5 (enExample) | 2021-10-07 |
| JP7257387B2 JP7257387B2 (ja) | 2023-04-13 |
Family
ID=65527860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512586A Active JP7257387B2 (ja) | 2017-08-29 | 2018-08-28 | スピロ環化合物並びにその作製及び使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11142526B2 (enExample) |
| EP (1) | EP3675847B1 (enExample) |
| JP (1) | JP7257387B2 (enExample) |
| KR (1) | KR20200046061A (enExample) |
| CN (1) | CN111050765B (enExample) |
| AU (1) | AU2018323459A1 (enExample) |
| BR (1) | BR112020004101A2 (enExample) |
| CA (1) | CA3072923A1 (enExample) |
| CL (1) | CL2020000462A1 (enExample) |
| CO (1) | CO2020001724A2 (enExample) |
| CR (1) | CR20200089A (enExample) |
| DO (1) | DOP2020000039A (enExample) |
| EA (1) | EA202090312A1 (enExample) |
| EC (1) | ECSP20013337A (enExample) |
| ES (1) | ES2952332T3 (enExample) |
| GE (1) | GEP20217327B (enExample) |
| IL (1) | IL272580B (enExample) |
| JO (1) | JOP20200023A1 (enExample) |
| MA (1) | MA50041A (enExample) |
| MX (1) | MX2020002251A (enExample) |
| NI (1) | NI202000014A (enExample) |
| PE (1) | PE20200664A1 (enExample) |
| PH (1) | PH12020500372A1 (enExample) |
| SG (1) | SG11202001022TA (enExample) |
| UA (1) | UA126685C2 (enExample) |
| WO (1) | WO2019046318A1 (enExample) |
| ZA (1) | ZA202001208B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| CN114096545A (zh) * | 2019-07-09 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 新杂环化合物 |
| EP4204420B1 (en) * | 2020-08-26 | 2024-08-07 | F. Hoffmann-La Roche AG | Heterocyclic compounds useful as magl inhibitors |
| UY39516A (es) * | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008109A (es) * | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| CA2665804A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8575296B2 (en) | 2009-09-29 | 2013-11-05 | Polyone Corporation | Polyester articles having simulated metallic or pearlescent appearance |
| DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| WO2011109277A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| SG11201807539UA (en) | 2016-03-31 | 2018-09-27 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| WO2018093950A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| AU2017361257B2 (en) | 2016-11-16 | 2022-02-10 | H. Lundbeck A/S. | Crystalline forms of a MAGL inhibitor |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
-
2018
- 2018-08-28 MX MX2020002251A patent/MX2020002251A/es unknown
- 2018-08-28 JP JP2020512586A patent/JP7257387B2/ja active Active
- 2018-08-28 UA UAA202001526A patent/UA126685C2/uk unknown
- 2018-08-28 EA EA202090312A patent/EA202090312A1/ru unknown
- 2018-08-28 CA CA3072923A patent/CA3072923A1/en active Pending
- 2018-08-28 JO JOP/2020/0023A patent/JOP20200023A1/ar unknown
- 2018-08-28 KR KR1020207008312A patent/KR20200046061A/ko not_active Ceased
- 2018-08-28 GE GEAP201815281A patent/GEP20217327B/en unknown
- 2018-08-28 IL IL272580A patent/IL272580B/en unknown
- 2018-08-28 CN CN201880056725.9A patent/CN111050765B/zh active Active
- 2018-08-28 BR BR112020004101-7A patent/BR112020004101A2/pt not_active IP Right Cessation
- 2018-08-28 US US16/642,717 patent/US11142526B2/en active Active
- 2018-08-28 CR CR20200089A patent/CR20200089A/es unknown
- 2018-08-28 AU AU2018323459A patent/AU2018323459A1/en not_active Abandoned
- 2018-08-28 PE PE2020000296A patent/PE20200664A1/es unknown
- 2018-08-28 WO PCT/US2018/048372 patent/WO2019046318A1/en not_active Ceased
- 2018-08-28 EP EP18850498.9A patent/EP3675847B1/en active Active
- 2018-08-28 SG SG11202001022TA patent/SG11202001022TA/en unknown
- 2018-08-28 MA MA050041A patent/MA50041A/fr unknown
- 2018-08-28 ES ES18850498T patent/ES2952332T3/es active Active
-
2020
- 2020-02-14 CO CONC2020/0001724A patent/CO2020001724A2/es unknown
- 2020-02-21 DO DO2020000039A patent/DOP2020000039A/es unknown
- 2020-02-21 EC ECSENADI202013337A patent/ECSP20013337A/es unknown
- 2020-02-24 PH PH12020500372A patent/PH12020500372A1/en unknown
- 2020-02-24 NI NI202000014A patent/NI202000014A/es unknown
- 2020-02-25 CL CL2020000462A patent/CL2020000462A1/es unknown
- 2020-02-26 ZA ZA2020/01208A patent/ZA202001208B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532545A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2020529994A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2019524883A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2017530959A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2018510139A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2017526674A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| RU2016137181A (ru) | Противофиброзные пиридиноны | |
| JP2010511721A5 (enExample) | ||
| JP2018513150A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2013507425A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2020502047A5 (enExample) |